|
業務類別
|
Biotechnology |
|
業務概覽
|
Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders. |
| 公司地址
| 234 Church Street, Suite 1020, New Haven, CT, USA, 06510 |
| 電話號碼
| +1 203 859-3820 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.rallybio.com |
| 員工數量
| 25 |
| Dr. Stephen Uden, M.D. |
Chief Executive Officer, President and Director |
美元 551.20K |
16/03/2026 |
| Mr. Jonathan I. Lieber, M.B.A. |
Principal Accounting Officer, Chief Financial Officer and Treasurer |
美元 478.40K |
16/03/2026 |
|
|
| Mr. Ronald M. Hunt, M.B.A. |
Independent Director |
16/03/2026 |
| Dr. Wendy K. Chung, M.D.,PhD |
Independent Director |
16/03/2026 |
| Dr. Lucian Iancovici, M.D. |
Independent Director |
16/03/2026 |
| Dr. Hui Liu, M.B.A.,PhD |
Independent Director |
16/03/2026 |
| Ms. Helen M. Boudreau, M.B.A. |
Independent Director |
16/03/2026 |
| Ms. Christine A. Nash, M.B.A. |
Independent Director |
16/03/2026 |
| Dr. Robert Hopfner, M.B.A.,PhD |
Independent Director |
16/03/2026 |
| Dr. Stephen Uden, M.D. |
Chief Executive Officer, President and Director |
16/03/2026 |
| Ms. Paula Soteropoulos |
Lead Independent Director |
16/03/2026 |
| Dr. Martin W. Mackay, PhD |
Chairman of the Board |
16/03/2026 |
|
|
|
|
